[HTML][HTML] Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy
C Chen, G Wang - World journal of hepatology, 2015 - ncbi.nlm.nih.gov
The incidence and mortality of hepatocellular carcinoma (HCC) have fallen dramatically in
China and elsewhere over the past several decades. Nonetheless, HCC remains a major …
China and elsewhere over the past several decades. Nonetheless, HCC remains a major …
[HTML][HTML] The role of branched-chain amino acid supplementation in combination with locoregional treatments for hepatocellular carcinoma: systematic review and …
GA Sideris, S Tsaramanidis, AT Vyllioti, N Njuguna - Cancers, 2023 - mdpi.com
Simple Summary The use of branched-chain amino acid (BCAA) supplements in patients
with cirrhosis and liver cancer has been investigated by numerous studies, with multiple …
with cirrhosis and liver cancer has been investigated by numerous studies, with multiple …
Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib
A Hiraoka, M Hirooka, Y Koizumi… - Hepatology …, 2017 - Wiley Online Library
Aim To elucidate the clinical significance of muscle wasting in regard to survival of
hepatocellular carcinoma (HCC) patients undergoing sorafenib treatment, we evaluated …
hepatocellular carcinoma (HCC) patients undergoing sorafenib treatment, we evaluated …
Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment
S Kamachi, T Mizuta, T Otsuka, S Nakashita… - Hepatology …, 2016 - Wiley Online Library
Background and Aim Sarcopenia, initially proposed as decreased of muscle mass and
strength, is associated with aging and malignant diseases. The aim of the present study was …
strength, is associated with aging and malignant diseases. The aim of the present study was …
[HTML][HTML] Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis
D Dong, JY Shi, X Shang, B Liu, WL Xu, GZ Cui… - Medicine, 2022 - journals.lww.com
Our study investigated the correlation between sarcopenia and clinical outcomes in patients
with hepatocellular carcinoma (HCC) treated with lenvatinib. We retrospectively evaluated …
with hepatocellular carcinoma (HCC) treated with lenvatinib. We retrospectively evaluated …
[HTML][HTML] Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku …
M Fujita, K Abe, H Kuroda, T Oikawa, M Ninomiya… - Scientific Reports, 2022 - nature.com
Sarcopenia is associated with poor prognosis of patients with hepatocellular carcinoma
(HCC). We investigated the association of skeletal muscle volume (SMV) and its change in …
(HCC). We investigated the association of skeletal muscle volume (SMV) and its change in …
Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease
AM van Dijk, AS Bruins Slot… - European journal of …, 2023 - Wiley Online Library
Background Dietary supplementation with branched‐chain amino acids (BCAA) is often
used in cirrhotic patients to improve nutritional status. We wanted to explore the evidence for …
used in cirrhotic patients to improve nutritional status. We wanted to explore the evidence for …
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real‐world practice
S Uchikawa, T Kawaoka, H Aikata… - Hepatology …, 2018 - Wiley Online Library
Aim As second‐line therapy, regorafenib has been shown to provide a survival benefit for
patients with hepatocellular carcinoma (HCC) who progress on sorafenib. In this …
patients with hepatocellular carcinoma (HCC) who progress on sorafenib. In this …
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: prospects for regorafenib therapy
T Terashima, T Yamashita, H Sunagozaka… - Hepatology …, 2018 - Wiley Online Library
Aim This study aimed to investigate liver functional reserves during sorafenib treatment for
advanced hepatocellular carcinoma (HCC), to identify predictive factors for maintaining …
advanced hepatocellular carcinoma (HCC), to identify predictive factors for maintaining …
[HTML][HTML] Skeletal muscle loss during multikinase inhibitors therapy: molecular pathways, clinical implications, and nutritional challenges
In cancer patients, loss of muscle mass is significantly associated with low tolerability of
chemotherapy and poor survival. Despite the great strides in the treatment of cancer …
chemotherapy and poor survival. Despite the great strides in the treatment of cancer …